Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-MBG/Marinobufagenin Antibody (3E9#)

Catalog #:   RGK61002 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: FCM, SPR
Expression system: Mammalian Cells
Overview

Catalog No.

RGK61002

Expression system

Mammalian Cells

Species reactivity

General

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Applications

FCM, SPR

Target

MBG, Marinobufagenin, Marinobufagin, Marinobufogenin

Concentration

0.22 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

ChEBI: 31319 & CAS: 465-39-4

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

3E9#

Note

For research use only.

Data Image
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior., PMID:27226628

Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction., PMID:27467458

Higher-Order Structure in Bacterial VapBC Toxin-Antitoxin Complexes., PMID:28271484

Impact of metric and sample size on determining malaria hotspot boundaries., PMID:28401903

On-slide detection of enzymatic activities in selected single cells., PMID:28872165

[A giant cell arteritis revealing a Goodpasture's syndrome]., PMID:29290619

Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction., PMID:29295972

A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement., PMID:29497000

Role of endogenous digitalis-like factors in the clinical manifestations of severe preeclampsia: a sytematic review., PMID:29930141

Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia., PMID:30104471

Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors., PMID:30409910

Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention., PMID:30460974

Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model., PMID:31153827

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up., PMID:31183384

Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats., PMID:31415452

Isolation and Characterization of Nanobodies against a Zinc-Transporting P-Type ATPase., PMID:31544889

Enzymatic activity in single cells., PMID:31668235

Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia., PMID:31713584

Milk osteopontin retains integrin-binding activity after in vitro gastrointestinal transit., PMID:31733850

[Review on anti-glomerular basement membrane disease or Goodpasture's syndrome]., PMID:31776042

[ANCA and anti-MBG double-positive vasculitis: An update on the clinical and therapeutic specificities and comparison with the two eponymous vasculitis]., PMID:31839271

Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties., PMID:31879340

The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus., PMID:31950036

A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system., PMID:32376685

Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement., PMID:32599335

An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase., PMID:32769120

A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity., PMID:32938727

Anca-positive vasculitis with full-house nephropathy, an unusual association: a case report and review of literature., PMID:33501927

Structural insights into the inhibition of glycine reuptake., PMID:33658720

Nanoscale spatial dependence of avidity in an IgG1 antibody., PMID:34135438

Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail., PMID:34201591

Alterations in Faecal Microbiota and Elevated Levels of Intestinal IgA Following Oral Administration of Lacticaseibacillus casei in mice., PMID:34676502

Medication-induced Pulmonary Injury: A Scenario- and Pattern-based Approach to a Perplexing Problem., PMID:34826256

Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients., PMID:34918048

Movement disorders associated with neuronal antibodies: a data-driven approach., PMID:35024921

Introducing Cysteines into Nanobodies for Site-Specific Labeling., PMID:35157281

Purpose-Built Immunoinformatics for BcR IG/TR Repertoire Data Analysis., PMID:35622343

Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era., PMID:36077782

Global circRNA expression changes predate clinical and histological improvements of psoriasis patients upon secukinumab treatment., PMID:36174034

Early computational detection of potential high-risk SARS-CoV-2 variants., PMID:36774893

eGFP as an All-in-One Tag for Purification of Membrane Proteins., PMID:37093475

[Anti-MBG crescentic glomerulonephritis with negative immunofluorescence: case report and literature review]., PMID:37179475

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab., PMID:37309201

Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndrome., PMID:37506503

Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity., PMID:37527039

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling., PMID:38036617

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines., PMID:38349280

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1., PMID:39097927

Antibody to Endogenous Cardiotonic Steroid Reverses Vascular Fibrosis and Restores Vasorelaxation in Chronic Kidney Disease., PMID:39201581

Neutralization of Marinobufagenin Demonstrates Efficacy In Vitro and In Vivo in Models of Pre-Eclampsia., PMID:40299324

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MBG/Marinobufagenin Antibody (3E9#) [RGK61002]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2026 AntibodySystem All Rights Reserved.            All Products are for Research Use Only